Aurobindo Pharma Shares Attract Attention Following US FDA Approval for Tofacitinib Tablets
Aurobindo Pharma Shares to Remain in Focus as USFDA Approves Generic Version of Xeljanz Tablets
Aurobindo Pharma shares are likely to remain in focus after the company received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Tofacitinib tablets, 5 mg and 10 mg, the generic version of PF Prism C.V.'s Xeljanz Tablets. The approved product is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis, active psoriatic arthritis, and moderately to severely active ulcerative colitis (UC).
The drug will be manufactured at APL Healthcare Unit IV, a wholly owned subsidiary of Aurobindo Pharma, and is set for an immediate launch in the US market. This development is significant for the company, which on June 3 inaugurated TheraNym, one of India's largest dedicated biologics contract manufacturing organisations (CMOs).
In the previous trading session, the share closed at Rs 1,463.60, up Rs 23.30, or 1.62 percent. The share touched a 52-week high of Rs 1,550.00 and a 52-week low of Rs 1,017.00 on 21 May, 2026 and 02 September, 2025, respectively. Currently, the stock is trading 5.57 percent below its 52-week high and 43.91 percent above its 52-week low.
Read also: Titan Stock Rides Bullish Sentiment Amid Optimism for Jewelry Growth
| Metric | Value |
|---|---|
| 52-week High | Rs 1,550.00 |
| 52-week Low | Rs 1,017.00 |
| Current Share Price | Rs 1,463.60 |
The market capitalisation of the company stands at Rs 85,006.13 crore.
Investor Takeaway
Aurobindo Pharma's shares may see a positive impact following the US FDA approval for Tofacitinib tablets.
More in Sector
Titan Stock Rides Bullish Sentiment Amid Optimism for Jewelry Growth
Titan Company: Prabhudas Lilladher Initiates Coverage with Buy Rating, Targets Rs 5161
Ultratech Cement: Target Price Set at Rs 13,835 by Prabhudas Lilladher
